Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Obesity

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher.

Benzinga

High demand expected for new daily weight loss pill

The tablet could be a cheaper and more convenient alternative to injections.

Evening Standard

New weight loss pill more ‘tolerable’ than jabs shown to be effective in key trial

The tablet could be a cheaper and more convenient alternative to injections

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)

Eli Lilly and Co. (NYSE:LLY) stock plunged on Thursday after the company released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

Benzinga

Five things I wish everyone knew about weight loss – by an expert in nutrition

Weight loss continues to dominate public discourse – often framed as a matter of personal responsibility. But after nearly 15 years working in and around health and nutrition research, I’ve seen how weight is treated differently from almost every other health issue.

The Conversation

Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply

Danish company to cut costs and consider layoffs after competition from Mounjaro and the copycat market

The Guardian - UK

Novo Nordisk keeps growing, fuelling hopes of a stock rebound

Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record share drop. Goldman Sachs says the sell-off is overdone and analysts highlight a potential buying opportunity.

Euronews

Read news from The Economist, FT, and more,
with one subscription

Obesity can be passed from parents to children. But do mothers’ or fathers’ genes matter more?

A new study suggests mothers’ genes could play an indirect role in shaping their children’s health, even when they aren’t passed on.

Euronews

OPINION - The real problem with Ozempic? The hell that comes after

It’s not actually that hard to imagine. Have you been on a diet? Have you ever lost weight? If so, the chances are you put that weight right back on again. I’ve done it. Oprah’s done it. Sam Smith have done it. My cat did it (RIP, my boy).

Evening Standard

Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign of deeper trouble ahead?

Barchart

Meet The Biotech Startup Challenging Ozempic With A Fat-Burning Pill That Lets You Keep Eating

Imagine shedding weight while sitting quietly watching TV, even without cutting calories. A pioneering pill called SANA, created by Uruguayan startup Eolo Pharma, could one day make that possible.

Benzinga

Trump officials plan coverage for weight loss drugs under Medicare and Medicaid

Pilot program, first pitched under Biden, will cover GLP-1 drugs such as Ozempic to address chronic obesity in US

The Guardian - US

Should You Buy the Post-Earnings Plunge in Novo Nordisk Stock or Stay Far, Far Away?

Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower over the next 12 months?

Barchart

Weight loss drugs could soon be used to treat these seven other health conditions

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Ultra-processed baby foods ‘set children up for lifetime of obesity,’ experts warn

A study has found that one in three baby food products as classed as ultra-processed foods

Benzinga

Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS'

Weight-loss drugmaker Novo Nordisk A/S (NYSE:NVO)’s technical chart is displaying a largely bearish trend amid a profit warning issued by the company tied to its blockbuster obesity drug Wegovy. However, this expert believes that the Danish pharmaceutical giant could have avoided some trouble if it hadn’t ended its partnership with…

The Independent UK

Walking fast for 15 minutes a day slashes risk of early death by 20%, study says

Researchers said a brief burst of speedy walking could help improve cardiovascular health and prevent obesity

Benzinga

Novo Nordisk Implodes After Wegovy Warning—Is The Weight-Loss Bubble Bursting?

Novo Nordisk A/S (NYSE:NVO) suffered its worst trading session on record Tuesday, plunging as much as 25% in European markets after issuing a surprise profit warning tied to its blockbuster obesity drug Wegovy and appointing a new CEO.

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews

Liver cancer cases could double by 2050. A new study says 60% are preventable

Experts call for urgent global action on hepatitis, alcohol, and obesity as new data shows that while preventable liver cancer cases are on the rise, the right mix of policy, prevention, and public awareness could save millions of lives.

The Guardian - UK

Lifestyle changes and vaccination ‘could prevent most liver cancer cases’

Lancet Commission says three in five cases preventable with action on obesity, alcohol and hepatitis

The Independent UK

The simple changes that could prevent three in five liver cancer cases

The majority of liver cancer cases are preventable

The Independent UK

What is liver cancer? Expert explains causes, symptoms and how to treat it

Many adults remain unaware of the risk factors for liver cancer

The Independent UK

The causes and treatments of liver cancer – as cases set to double fuelled by obesity

Many adults remain unaware of the risk factors, with obesity a major factor.

Evening Standard

Obesity to fuel rise in liver cancer cases – study

By 2025, 11% of liver cancers will be linked to obesity.

The Independent UK

Weight-loss jabs could help obese people control asthma, study suggests

A number of types of the drug are recommended to help tackle obesity on the NHS.

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the University of Leeds

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.